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Sir,
We would like to thank Grizzi et al for their comments to our paper
on the expression of tumour antigens in hepatocellular carcinoma
(HCC) in a Western European cohort (Sideras et al, 2015). Grizzi et al
discuss the international collaborative efforts organised by the ‘Society
for Immunotherapy of Cancer’ with a goal to ‘identify hurdles that
impede effective translation of cancer immunotherapy’ (Fox et al,
2011). One of the hurdles the panel identified was that of cancer
complexity. The question arises if studies using tissue microarrays
(TMAs) are capable of capturing the complexity of cancer. To answer
the question it is important to first consider not only the disadvantages
but also the advantages of TMA-based research, and to understand
which research question is being asked by the investigators using
TMAs.
Tissue microarray technology was developed as an alternative to
laborious and costly histological studies utilising full tissue slides
(Camp et al, 2008). The advantages are several. Tissue microarrays
use small amounts of tissue that markedly increase the number of
assays that can be performed per tissue block. In fact, the tissue blocks
we used for our study are largely undisturbed after cutting the cores
and can be further used to study other questions. Tissue microarrays
substantially reduce the amount of antibodies and workload when
studying large cohorts of patients. The presence of tissues from
multiple patients on a single slide allows for identical experimental
conditions.
As pointed out by Grizzi et al, a potential disadvantage of using TMAs
is that, in case of tumour heterogeneity, antigens of interest, which are
focally expressed, may be missed. However, multiple studies have
demonstrated strong correlations between TMAs and whole sections
(Camp et al, 2000; Torhorst et al, 2001; O’Grady et al, 2003; Zhang et al,
2003; Bhargava et al, 2004; Schmidt et al, 2009), and it is known that
sampling error is reduced inversely to the size of the cohort. Although
the correlation also depends on the level of heterogeneity, even
heterogeneously expressed antigens have shown reasonable correlations
between TMAs and full sections (Camp et al, 2008).
To come back to our study, several cancer testis antigens (CTAs)
showed lower prevalence of expression than studies originating in
Eastern Asia, where most HCC patients are HBV positive. We provided
several explanations to account for these discrepancies. One of them is
the discrepancy in aetiology (in our study only 23% of patients were
HBV positive), which has been previously shown to influence the
expression of CTAs. For example, in the study by Xia et al, which is
quoted by Grizzi et al, the prevalence of MAGE-C1 expression, as
examined in full-tumour sections of 46 patients, was 36% (Xia et al,
2013). However, in HBV-negative patients only 13% expression was seen,
in agreement with our study. We further discussed how our results are in
agreement with other similar studies from European cohorts with low
HBV prevalence (Riener et al, 2009). On the contrary, the Liang et al
study, also quoted, had an HBV prevalence of 88% (Liang et al, 2013).
Incidentally, Liang et al also used TMAs to study CTA expression of the
362 HCC patients in their study. The study by Wang et al, which was not
published at the time of submission of our paper, examined tissue from
142 patients using RT–PCR (Wang et al, 2015). However, as we
discussed in our paper, mRNA is not always translated to protein, and in
fact direct comparisons have shown much lower CTA protein expression
than mRNA expression in HCC (Nakamura et al, 2006).
A final point raised by Grizzi et al is regarding the use of the H-score.
We agree that this method provides equivalent mathematical products
that ‘may’, biologically, represent different things. We used the
H-score only to investigate the possible biologic role of Glypican-3
and SALL-4 co-expression, and we were quite cautious as to the
drawn conclusions, indicating that more research is needed to establish
such an association. On the other hand, in Figure 2 of our manuscript,
we show three-dimentional graphs of the intensities and percentages
of expression of several tumour antigens, providing thus a transparent
view of our data.
In conclusion, although we agree with Grizzi et al that TMAs are
not suitable for answering questions of complex spatial relationships
in the tumour microenvironment, or selection of tumour antigens for
immunotherapeutic targeting in individual patients, our aim, to compare
expression prevalence of a large panel (15) of tumour antigens in HCC,
using a relatively large patient cohort (131), justifies the use of TMAs.
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